FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063351090> ?p ?o ?g. }

• W2063351090 endingPage "241" @default.
• W2063351090 startingPage "241" @default.
• W2063351090 abstract "Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia Ann Janssens, Marc Boogaerts, Gregor VerhoefDepartment of Hematology, University Hospitals Leuven, Campus Gasthuisberg, Leuven, BelgiumAbstract: Fludarabine is an antineoplastic agent used in the treatment of hematological malignancies, particularly chronic lymphocytic leukemia (CLL) and indolent B-cell lymphoma. Because of its immunosuppressive effects, fludarabine has been added to reduced intensity conditioning regimens. The oral formulation of fludarabine has become widely available. Pharmacokinetic studies have shown that an oral dose of 40 mg/m2/d would provide systemic drug exposure similar to the standard intravenous (IV) dose of 25 mg/m2/d. The oral dose can be taken once daily without any dietary restrictions. Dose adjustments are mandatory in patients with renal impairment to avoid increased toxicity. Several noncomparative trials in previously untreated and treated patients with CLL have shown that treatment with the oral formulation demonstrates similar efficacy compared to historical control groups treated with the IV formulation. The tolerability profile of oral fludarabine seems similar to that of the IV formulation. Myelosuppression and infectious complications are the most frequently reported adverse events. Gastrointestinal toxicity is more frequent with the oral formulation, but is usually of mild or moderate severity. Although oral fludarabine makes treatment more convenient, health care workers must be aware of the compliance behavior of each patient. Keywords: CLL, treatment, oral fludarabine, intravenous fludarabine" @default.
• W2063351090 created "2016-06-24" @default.
• W2063351090 creator A5024744415 @default.
• W2063351090 creator A5062839406 @default.
• W2063351090 creator A5069303553 @default.
• W2063351090 date "2009-10-01" @default.
• W2063351090 modified "2023-09-30" @default.
• W2063351090 title "Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia" @default.
• W2063351090 cites W123131416 @default.
• W2063351090 cites W1494274243 @default.
• W2063351090 cites W15646161 @default.
• W2063351090 cites W1826504911 @default.
• W2063351090 cites W1906996655 @default.
• W2063351090 cites W1930759119 @default.
• W2063351090 cites W1935154669 @default.
• W2063351090 cites W1939111644 @default.
• W2063351090 cites W1944363718 @default.
• W2063351090 cites W1965641972 @default.
• W2063351090 cites W1974382233 @default.
• W2063351090 cites W1976327976 @default.
• W2063351090 cites W1980967432 @default.
• W2063351090 cites W1995705474 @default.
• W2063351090 cites W1995916528 @default.
• W2063351090 cites W2011008588 @default.
• W2063351090 cites W2013756909 @default.
• W2063351090 cites W2013763814 @default.
• W2063351090 cites W2013788041 @default.
• W2063351090 cites W2013834476 @default.
• W2063351090 cites W2015120596 @default.
• W2063351090 cites W2016875693 @default.
• W2063351090 cites W2017317390 @default.
• W2063351090 cites W2018295586 @default.
• W2063351090 cites W2038105958 @default.
• W2063351090 cites W2043962116 @default.
• W2063351090 cites W2053682097 @default.
• W2063351090 cites W2053683902 @default.
• W2063351090 cites W2055131118 @default.
• W2063351090 cites W2070193300 @default.
• W2063351090 cites W2071906414 @default.
• W2063351090 cites W2082356967 @default.
• W2063351090 cites W2107567250 @default.
• W2063351090 cites W2126442701 @default.
• W2063351090 cites W2127877465 @default.
• W2063351090 cites W2130037808 @default.
• W2063351090 cites W2135270635 @default.
• W2063351090 cites W2137804513 @default.
• W2063351090 cites W2142195688 @default.
• W2063351090 cites W2142983050 @default.
• W2063351090 cites W2151358460 @default.
• W2063351090 cites W2153334574 @default.
• W2063351090 cites W2153809930 @default.
• W2063351090 cites W2161926682 @default.
• W2063351090 cites W2162645459 @default.
• W2063351090 cites W2171425315 @default.
• W2063351090 cites W2263307479 @default.
• W2063351090 cites W2326175431 @default.
• W2063351090 cites W2327788740 @default.
• W2063351090 cites W2348637346 @default.
• W2063351090 cites W2550364204 @default.
• W2063351090 cites W2556217933 @default.
• W2063351090 cites W2570172189 @default.
• W2063351090 cites W2592196653 @default.
• W2063351090 cites W291054678 @default.
• W2063351090 cites W2979365039 @default.
• W2063351090 cites W3191329923 @default.
• W2063351090 cites W60865865 @default.
• W2063351090 cites W61258569 @default.
• W2063351090 cites W61375579 @default.
• W2063351090 cites W65919465 @default.
• W2063351090 cites W96780237 @default.
• W2063351090 cites W2101252134 @default.
• W2063351090 doi "https://doi.org/10.2147/dddt.s5603" @default.
• W2063351090 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2802124" @default.
• W2063351090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20054443" @default.
• W2063351090 hasPublicationYear "2009" @default.
• W2063351090 type Work @default.
• W2063351090 sameAs 2063351090 @default.
• W2063351090 citedByCount "8" @default.
• W2063351090 countsByYear W20633510902012 @default.
• W2063351090 countsByYear W20633510902013 @default.
• W2063351090 countsByYear W20633510902014 @default.
• W2063351090 countsByYear W20633510902015 @default.
• W2063351090 countsByYear W20633510902020 @default.
• W2063351090 countsByYear W20633510902021 @default.
• W2063351090 countsByYear W20633510902022 @default.
• W2063351090 crossrefType "journal-article" @default.
• W2063351090 hasAuthorship W2063351090A5024744415 @default.
• W2063351090 hasAuthorship W2063351090A5062839406 @default.
• W2063351090 hasAuthorship W2063351090A5069303553 @default.
• W2063351090 hasBestOaLocation W20633510901 @default.
• W2063351090 hasConcept C126322002 @default.
• W2063351090 hasConcept C143998085 @default.
• W2063351090 hasConcept C194409129 @default.
• W2063351090 hasConcept C197934379 @default.
• W2063351090 hasConcept C2776694085 @default.
• W2063351090 hasConcept C2776755627 @default.
• W2063351090 hasConcept C2777938653 @default.
• W2063351090 hasConcept C2778375690 @default.

• next